In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO’s Mode of Action
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that it will hold an in-person and virtual R&D day on Thursday, May 30, 2024 at 3:00 PM CET (9:00 AM ET). The event will be held at Inderes Event Studio, Västra Trädgårdsgatan 19, Stockholm.The event will feature Gareth J. Thomas, PhD (University Hospital Southampton) and Jonathan Barratt, PhD, FRCP (University of Leicester) with the following program: · Supportive preclinical data and Phase 2 POC trial evaluating setanaxib, the Company's lead candidate from its NOX platform, in patients